# Jinling Hospital, China: Phase 1 study in Sperm DNA Fragmentation (114 participants)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Jinling Hospital, China |
| Sponsor type | Academic and hospital |
| Study | HMG Treatment Reduces Sperm DNA Fragmentation |
| NCT ID | NCT07873502 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Sperm DNA Fragmentation |
| Intervention types | drug |
| Target enrollment | 114 |
| Site countries | China |
| Posted | 2026-10-14 |
| Planned start | 2025-07-02 |
| Event | Newly registered study |
| Event date | 2026-10-14 |

## Why this score
- 114 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07873502). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.